# NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

> **NCT05020678** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nkarta, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- B-cell Acute Lymphoblastic Leukemia
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Indolent Lymphoma
- Waldenstrom Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Aggressive Lymphoma
- Large-cell Lymphoma

## Interventions

- **BIOLOGICAL:** NKX019

## Key facts

- **NCT ID:** NCT05020678
- **Lead sponsor:** Nkarta, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-20
- **Primary completion:** 2025-03-31
- **Final completion:** 2038-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020678, "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05020678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*